
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical Co is positioned for continued growth as it anticipates a 7% year-over-year sales increase in 2026, building on a strong normalized base of $146 million in 2025, with expectations for share gains in the implantable Collamer lens market. Potential drivers of this positive outlook include the accelerated domestic launch of the EVO lens, increased market share within the refractive error correction segment, and improved profit margins leading to stronger earnings per share growth. The company's strategic initiatives, led by CEO Steve Farrell, aim to streamline operations and enhance cost structures, further solidifying its competitive edge in the global refractive market.
Bears say
Staar Surgical Co. faces a negative outlook due to several fundamental issues reflected in its financial performance metrics. The company's normalized adjusted EBITDA of $6.7 million was significantly impacted by a $27.5 million revenue decrease linked to high inventory levels with a new distributor in China, which raises concerns about both immediate results and future guidance. Additionally, potential risks associated with declining revenue in China, increased competition from lower-cost alternatives, and broader macroeconomic challenges further exacerbate the uncertainty surrounding Staar's financial stability and growth prospects.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares